OTO Fertility

What OTO Fertility does

OTO Fertility is a digital health division of OTO Coach that operates an AI-powered biometric platform paired with a clinical-grade biosensor (and a wrist-worn successor called OTO Cira) to predict fertility treatment outcomes for IVF, IUI, unexplained infertility, and egg-freezing patients. The platform captures over 50 physiological signals — including ECG at greater than 500 Hz, EEG-derived DC potential, heart rate variability, and amplitude-frequency analysis — and processes them through 50+ proprietary algorithms to generate a daily Fertility Index score and identify an optimal "Fertility Zone" for conception. The technology traces its lineage to 1984 NASA space-medicine bioscience, evolved through the Omegawave performance platform used by elite athletes, and was acquired by OTO in 2022 before being adapted for reproductive health. The chest biosensor received FDA clearance, and manufacturing is certified under ISO 9001:2015 and ISO 13485:2016.

OTO Fertility distributes exclusively through a B2B2C model via partner fertility clinics across North America, including Inception Fertility, Boston IVF, Pacific Northwest Fertility, and an online partner, Monday Fertility. The company monetizes through hardware kits and a revenue-sharing subscription arrangement with clinics, while a companion OTO Life App delivers daily Fertility Index data and stress-regulation tools to patients. A scientific advisory board spanning Harvard, McMaster, Stanford, UCSF, ULB, Tampere, and Queens provides clinical credibility, and reported outcomes include 77-85% pregnancy rates among patients who achieve the Fertility Zone and an approximately 2.5-year reduction in time-to-pregnancy versus standard of care. With 1-10 employees, no disclosed funding rounds or revenue figures, and a December 2025 commercial launch followed by a CES 2026 unveiling of the Cira wristband (available end of 2026), OTO Fertility is positioned in the earliest stage of commercial scaling, targeting a femtech and wearable-fertility-tracker market that is projected to grow from $1.01B in 2025 to $1.88B by 2030.

Name

OTO Fertility

Legal name

OTO Fertility

Website

https://otofertility.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

1–10 employees

Short description

OTO Fertility is a division of OTO Coach that sells an FDA-cleared AI-powered biosensor platform, plus the OTO Cira wrist wearable, to fertility clinics across North America to predict IVF and conception outcomes by monitoring over 50 physiological signals including ECG, HRV, and EEG-derived biomarkers.

Ownership category

akta.pro rank

Product category

Fertility Health Technology

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Fertility & Reproductive Endocrinology Telehealth (IVF/IUI, infertility evaluation) (HLALAHAA)

akta.pro secondary industry

Women’s Health & Fertility Tracking Devices (Ovulation/Temp Sensors, Pelvic Health Devices) (CRACAQAJ)

Keywords

• Fertility health monitoring
• Wearable biosensor devices
• Stress physiology analytics
• Reproductive health platform
• Predictive fertility analysis

Headquarters

HQ city

Richmond Hill

HQ country

Canada

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations, Infrastructure

Revenue model

1. Clinical Biosensor Hardware: Patients receive a clinical-grade biosensor device as part of their OTO Fertility kit, administered through partner clinics. This represents a hardware component revenue stream integrated into the clinic-based care pathway.
2. Clinic Subscription / Revenue Sharing: OTO Fertility operates through partner fertility clinics with a revenue-sharing model. Clinics integrate the platform into their care offerings, with the company monetizing through this B2B2C distribution arrangement. Revenue flows from clinics paying for access to the platform and sharing in patient outcomes.
3. Software Platform Access (OTO Life App): The companion OTO Life App provides the daily Fertility Index, insights, stress-regulation tools, and progress tracking. While distributed through clinics, this represents an ongoing software access component tied to the subscription model.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

OTO Fertility provides an AI-powered biometric platform with FDA-cleared clinical-grade biosensors (chest-worn and wrist-worn) that capture ECG, HRV, and EEG-derived signals to generate a daily proprietary Fertility Index. The platform employs 50+ proprietary algorithms to analyze 1,900+ physiological features per user across six IVF cycle phases, identifying optimal Fertility Zone periods and predicting pregnancy probability. Products are sold through a B2B2C distribution model exclusively via partner fertility clinics across North America, with revenue shared between the company and its clinical partners.

Product overview

OTO Fertility is a clinical-grade digital health platform consisting of multiple integrated products: the OTO Fertility Biosensor (chest-worn clinical device), OTO Cira™ wristband (wearable form factor launching 2026), OTO Life App (mobile dashboard), and OTO Insights™ (proprietary analytics engine). The system monitors over 50 physiological signals including ECG, HRV, EEG, and stress biomarkers, synthesizing them into a daily Fertility Index score that identifies a woman's 'Fertility Zone'—the optimal physiological state for conception. Products are distributed exclusively through partner fertility clinics across North America.

Differentiator

Problem solved

Functional benefit

Brands

• OTO Cira: World's first wrist-worn biosensor designed to predict fertility success with clinical-grade accuracy. Captures ECG, HRV, and EEG-derived signals throughout fertility and pregnancy. Scheduled for availability in 2026.
• OTO Life App
• OTO Insights

Products and services

• OTO Fertility Biosensor Clinical-grade chest biosensor that captures ECG signals at >500 Hz and EEG readings to measure autonomic and central nervous system activity for fertility prediction and stress physiology assessment.
• OTO Cira World's first wrist-worn biosensor designed to predict fertility success with clinical-grade accuracy, extending OTO's electrophysiological monitoring to a more convenient wristband form factor.
• OTO Life App Secure digital hub providing daily Fertility Index display, personalized insights, stress-regulation tools, and progress tracking for fertility patients and clinicians.
• OTO Insights Proprietary AI algorithm system that transforms complex biometrics into actionable fertility guidance, evaluating autonomic and CNS balance, stress resilience, and adaptive capacity across six IVF cycle phases.

Quantifiable outcome

• 77% pregnancy rate for women who achieve OTO Fertility Zone
• +4 more outcomes

Named customers7 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature7 records

Partnerships

Twelve partnerships are on record, tiered core and supporting.

• Harvard UniversitycoreStrategic or Co-development PartnerDr. Alice Domar, Associate Professor at Harvard, serves on the OTO Fertility Scientific Advisory Board. Dr. Domar is a renowned reproductive health psychologist who developed one of the first mind-body programs for infertility, providing clinical credibility and research collaboration.
• McMaster UniversitycoreStrategic or Co-development PartnerDr. Mark Tarnopolsky, Division Head of Neurometabolic Disorders at McMaster University's Cumming School of Medicine, serves on the scientific advisory board, contributing expertise in exercise physiology and metabolic health research.
• Inception FertilitycoreStrategic or Co-development PartnerDr. Alice Domar serves as Chief Compassion Officer at Inception Fertility. Strategic advisory relationship connecting OTO with major fertility network.
• Pacific Northwest FertilitycoreChannel Partner/ Reseller/ DistributorDr. Lora Shahine, Medical Director at Pacific Northwest Fertility, serves on the advisory board. Key clinic partner with testimonials referencing OTO integration.
• Boston IVFcoreChannel Partner/ Reseller/ DistributorHillary Wright, Director of Nutrition at Boston IVF, serves on the advisory board, providing integration pathway for clinical deployment.
• Monday FertilitysupportingChannel Partner/ Reseller/ DistributorOnline partner clinic providing access to OTO Fertility for patients without local partner clinics. Enables nationwide accessibility beyond physical clinic locations.
• Government of OntariosupportingStrategic or Co-development PartnerStrategic partner providing institutional credibility and regional support in Ontario, Canada.
• Fertility AlbertasupportingChannel Partner/ Reseller/ DistributorRegional fertility organization partner providing clinic network access in Alberta, Canada.
• Fertility Matters CanadasupportingGTM or Marketing PartnerNational fertility advocacy organization partnership for awareness and patient outreach in Canada.
• RESOLVE: The National Infertility AssociationsupportingGTM or Marketing PartnerUS-based infertility advocacy organization partnership for patient support and awareness programs.
• InceptioncoreStrategic or Co-development PartnerMajor fertility network partner. Dr. Alice Domar serves as Chief Compassion Officer. Strategic relationship for broad clinic network integration.
• NASAcoreTechnology or IntegrationOriginal technology foundation derived from NASA-developed bioscience for astronauts. Space medicine origins (1984) provide foundational technology licensing and scientific credibility.

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Apple (Apple Watch Health): Apple Watch includes cycle tracking, ECG, HRV, and general health features increasingly used by women tracking fertility. Massive consumer incumbent whose platform features compete for the same end-user attention and may integrate basic fertility tracking that OTO must differentiate against.
• Oura: Established smart ring with cycle tracking, HRV, readiness, and sleep features used by a broad consumer base including women tracking fertility. Broad incumbent in the personal health wearable space whose fertility features compete for the same consumer attention, though not specifically fertility-focused.

Direct peers

• Mira: Hormone-based at-home fertility tracking system measuring actual hormone concentrations in urine to predict ovulation and fertile window. Direct competitor offering an alternative diagnostic approach to OTO's ECG/EEG-based biosensor, targeting similar TTC and fertility-clinic patients.
• Inito: At-home fertility monitor that measures multiple hormones (E3G, PdG, FSH, LH) via urine test strips. Direct competitor in the connected fertility diagnostic category with a similar home-test-plus-app value proposition, but using a fundamentally different biomarker approach.
• Modern Fertility (Ro): Women's reproductive health testing and education company (acquired by Ro) offering at-home hormone tests and fertility insights. Comparable as a consumer-facing fertility diagnostic brand focused on personalization and clinical validity, though primarily test-based rather than wearable-based.
• Tempdrop: Wearable basal body temperature sensor designed for continuous overnight fertility charting. Competes with OTO in the consumer fertility tracking wearable space, particularly for women seeking non-invasive cycle monitoring.
• Ava Science: Consumer fertility tracking bracelet using skin temperature, HR, HRV, and other physiological signals to identify the fertile window. Direct competitor in the wearable fertility tracking category targeting the same trying-to-conceive consumer, though OTO positions itself at higher clinical-grade accuracy.

Regional players

• Genea Biomedx: Australia-based fertility technology company developing lab instruments and software for IVF clinics. Regional peer with clinic-channel B2B distribution model and IVF technology focus, comparable to OTO's clinic-centric B2B2C approach but with different product category.

Emerging players

• Elvie: Women's health technology company best known for connected pelvic floor devices and smart breast pumps. Adjacent FemTech player with shared consumer demographic and brand positioning around women's health, though different primary use cases than OTO's fertility diagnostics.
• Maven Clinic: Virtual care platform for women's and family health spanning fertility, pregnancy, postpartum, and pediatrics. Comparable as a digital health company serving the fertility care journey, though more focused on telehealth consultations than biosensor diagnostics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/otofertility

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OTO Fertility